Florida Orthopaedic Institute, Adult Reconstruction, Tampa, FL.
Florida Orthopaedic Institute, Adult Reconstruction, Tampa, FL; Department of Orthopaedics, University of South Florida College of Medicine, Tampa, FL.
J Arthroplasty. 2022 Sep;37(9):1726-1730. doi: 10.1016/j.arth.2022.04.005. Epub 2022 Apr 9.
No evidence-based guidelines exist for the perioperative use of clopidogrel in elective hip and knee arthroplasty patients. This study compares the preoperative, intraoperative, and postoperative outcomes of total hip and knee arthroplasty in patients maintained on clopidogrel and with patients whose clopidogrel was held before surgery.
We retrospectively identified 158 patients taking clopidogrel before undergoing elective total hip or knee arthroplasty. Patients were stratified for having clopidogrel held or continued, based on the interval between latest dose and date of surgery. The primary end points were receipt of transfusion and readmission within 90 days of surgery. Secondary end points were the incidence of complications such as bleeding, infection, re-operation, and major cardiac or neurologic events such as myocardial infarction or stroke during the 90-day postoperative period.
The two cohorts had similar demographics. Patients who continued clopidogrel were more likely to receive a blood transfusion postoperatively (9.1% vs 0%, P = .005), but there was no difference in wound drainage (P = .65), wound infection (P = .24), readmission (P = .74), major complications (P = .64), length of stay (P = .70), or mortality (P = .42). Patients who continued clopidogrel before surgery were more likely to have received general anesthesia (P < .001) per anesthesia protocol, however, three such patients did receive spinal anesthesia without any complications. With cementless implants, blood loss was not different between clopidogrel groups.
Patients undergoing elective total hip and knee arthroplasty may be safely maintained on clopidogrel without an increased risk of wound complications, infections, length of stay, readmission, reoperation, major medical complications, or mortality. Further prospective research is warranted to confirm the effects of continuing clopidogrel in patients undergoing elective hip and knee arthroplasty.
目前尚无循证医学指南指导择期髋关节和膝关节置换术患者围手术期氯吡格雷的使用。本研究比较了继续使用氯吡格雷和术前停用氯吡格雷的髋关节和膝关节置换术患者的术前、术中及术后结局。
我们回顾性地确定了 158 例在择期全髋关节或全膝关节置换术前服用氯吡格雷的患者。根据末次剂量与手术日期之间的间隔,将患者分为氯吡格雷继续使用或停药组。主要终点为术后 90 天内输血和再入院。次要终点为术后 90 天内出血、感染、再次手术以及主要心脏或神经系统事件(如心肌梗死或中风)的发生率。
两组患者的人口统计学特征相似。继续使用氯吡格雷的患者术后更有可能输血(9.1% vs. 0%,P=0.005),但伤口引流量(P=0.65)、伤口感染(P=0.24)、再入院(P=0.74)、主要并发症(P=0.64)、住院时间(P=0.70)或死亡率(P=0.42)差异无统计学意义。根据麻醉方案,继续使用氯吡格雷的患者更有可能接受全身麻醉(P<0.001),但有 3 例患者接受了椎管内麻醉,没有出现任何并发症。使用非骨水泥假体时,氯吡格雷组之间的失血量无差异。
择期全髋关节和全膝关节置换术患者继续使用氯吡格雷不会增加伤口并发症、感染、住院时间、再入院、再次手术、主要医疗并发症或死亡率的风险。需要进一步前瞻性研究证实继续使用氯吡格雷对择期髋关节和膝关节置换术患者的影响。